Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants

Table 3 Comparison of platelet VEGF and plasma sVEGFR-2 per treatment groups in the CENTAURO-2 trial

Groups	pg of VEGF/10⁶platelets Mean (range) [n]		pg/mL of sVEGFR-2 Mean (range) [n]
	Week 0	Week 13	Week 0	Week 13
Ag + V	1.21 (0.30–2.20) [7]	0.61 (0.10–1.43) [7] ns	9736 (6939–11724) [7]	9792 (7427–11162) [7] ns
Ag + 2 V	0.93 (0.55–1.46) [7]	1.01 (0.08–3.29) [7] ns	10455 (8116–12653) [8]	10423 (7262–12882) [8] ns
2Ag + V	2.07 (0.11–8.19) [8]	0.57 (0.22–2.05) [8] p = 0.0244*	9736 (7078–12637) [8]	9948 (9125–11098) [8] ns
½Ag + Al	1.90 (0.90–3.64) [8]	1.98 (0.63–3.54) [8] ns	10228 (7555–12735) [8]	9567 (7820–13372) [8] ns
Ag + Al	1.58 (0.72–3.19) [8]	1.06 (0.15–2.91) [8] p = 0.0086**	10131 (8491–12223) [8]	10296 (8611–13294) [8] ns

The table summarizes the data per vaccine dose cohorts and the results of paired t-test (ns: non-significant; *p < 0.05; **p < 0.01). (n) number of patients

ISSN: 1471-2172